Research Summary

I am a Medical Oncologist within the Division of Hematology/Oncology at the University of California San Francisco. My clinical practice focuses on patients with advanced solid tumor malignancies with a particular emphasis on genitourinary malignancies including prostate, kidney, bladder, and testicular cancer. I serve as the Co-Leader for the GU Medical Oncology program at UCSF.

My research focus is on developing novel therapies and imaging modalities for patients with advanced solid tumor malignancies, with a focus on patients with advanced prostate cancer.

Research Funding

  • March 1, 2021 - February 28, 2026 - Precision targeting of T cell cytotoxicity with PET , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA258297
  • December 1, 2020 - November 30, 2025 - Measuring Metabolic Activity in Prostate Cancer Bone Metastases Using Hyperpolarized 13C Pyruvate MRI for Improved Targeted Therapy Monitoring , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA256740
  • June 1, 2017 - May 31, 2022 - Targeting Neuroendocrine Prostate Cancer Using Multi-Probe Hyperpolarized 13C MRI for Improved Treatment and Therapeutic Monitoring , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA215694
  • June 1, 2019 - April 30, 2021 - Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate Cancer , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA229354

Education

Northwestern University, Evanston, IL, BA, 1999-2002, Psychology
Northwestern University Feinberg School of Medicine, Chicago, IL, MD, 2002-2006, Medicine

Honors & Awards

  • 2001
    James Alton James Scholarship, Northwestern University
  • 2002
    James A. Patten Scholarship, Northwestern University
  • 2002
    Phi Beta Kappa Centennial Award, Northwestern University
  • 2002
    Summa Cum Laude, Northwestern University
  • 2004
    Department of Medicine Chairman’s Award, Northwestern University School of Medicine
  • 2005
    Member Alpha Omega Alpha medical honor society
  • 2011
    Pfizer Fellowships in Oncology Award in collaboration with UCSF Division of Hematology/Oncology, Department of Medicine
  • 2012
    Young Investigator Award, American Society of Clinical Oncology/Conquer Cancer Foundation
  • 2012
    Inaugural Recipient, Ronald A. Rosenberg Fellowship in Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2013
    Alliance Cooperative Group Scholar Award
  • 2014
    The Sence Foundation Award
  • 2015
    Prostate Cancer Foundation Young Investigator Award
  • 2016
    Department of Defense Prostate Cancer Research Program Physician Research Training Award
  • 2016
    UCSF Helen Diller Family Early Phase Clinical Research Support Grant
  • 2016
    National Cancer Institute Cancer Clinical Investigator Team Leadership Award

Selected Publications

  1. Paydary K, DeLuca A, Aggarwal R, Wall L, Stadler WM. Enrollment Barriers for Molecular Targeted Trials. JAMA Oncol. 2023 Apr 06.  View on PubMed
  2. Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou J, Friedlander T, Koshkin VS. Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. Front Oncol. 2023; 13:1161089.  View on PubMed
  3. Bidkar AP, Wang S, Bobba KN, Chan E, Bidlingmaier S, Egusa EA, Peter R, Ali U, Meher N, Wadhwa A, Dhrona S, Dasari C, Beckford-Vera D, Su Y, Tang R, Zhang L, He J, Wilson DM, Aggarwal R, VanBrocklin HF, Seo Y, Chou J, Liu B, Flavell RR. Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy. Clin Cancer Res. 2023 Mar 14.  View on PubMed
  4. Lim EA, Schweizer MT, Chi KN, Aggarwal R, Agarwal N, Gulley J, Attiyeh E, Greger J, Wu S, Jaiprasart P, Loffredo J, Bandyopadhyay N, Xie H, Hansen AR. Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2023 Feb 28.  View on PubMed
  5. Kwon DH, Aggarwal RR. Intermittent Hormonal Therapy in Biochemical Recurrence of Prostate Cancer Is Worth Considering Because of Mitigation of Cardiovascular Events and Reduction of Other Effects. Eur Urol Focus. 2023 Jan 21.  View on PubMed
  6. Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, Hashemi Sadraei N, Yu B, Salvati M, Bailis JM, Feng FY, Flavell RR, Aggarwal R. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer. Cancer Res. 2023 01 18; 83(2):301-315.  View on PubMed
  7. Kwon DH, Gordon KM, Tong B, Borno HT, Beigh M, Fattah D, Schleicher A, Aggarwal RR, Blanco AM, Small EJ, Dhawan M. Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer. JCO Oncol Pract. 2023 Jan 12; OP2200638.  View on PubMed
  8. Feng E, Rydzewski NR, Zhang M, Lundberg A, Bootsma M, Helzer KT, Lang JM, Aggarwal R, Small EJ, Quigley DA, Sjöström M, Zhao SG. Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 12 15; 28(24):5396-5404.  View on PubMed
  9. Langlais CS, Chen YH, Van Blarigan EL, Chan JM, Ryan CJ, Zhang L, Borno HT, Newton RU, Luke A, Bang AS, Panchal N, Tenggara I, Schultz B, Lavaki E, Pinto N, Aggarwal R, Friedlander T, Koshkin VS, Harzstark AL, Small EJ, Kenfield SA. Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention. Urol Oncol. 2023 Mar; 41(3):146.e1-146.e11.  View on PubMed
  10. Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. Urol Oncol. 2023 Mar; 41(3):145.e7-145.e15.  View on PubMed
  11. Su CT, Nizialek E, Berchuck JE, Vlachostergios PJ, Ashkar R, Sokolova A, Barata PC, Aggarwal RR, McKay RR, Agarwal N, McClure HM, Nafissi N, Bryce AH, Sartor O, Sayegh N, Cheng HH, Adra N, Sternberg CN, Taplin ME, Cieslik M, Alva AS, Antonarakis ES. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer. Prostate. 2023 02; 83(3):227-236.  View on PubMed
  12. Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist. 2022 11 03; 27(11):940-951.  View on PubMed
  13. Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Res. 2022 11 02; 82(21):3888-3902.  View on PubMed
  14. Aggarwal R, Alumkal JJ, Szmulewitz RZ, Higano CS, Bryce AH, Lopez-Gitlitz A, McCarthy SA, Miladinovic B, McQuarrie K, Thomas S, Zhang K, Small EJ. Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer. Prostate Cancer. 2022; 2022:5454727.  View on PubMed
  15. Aggarwal R, Starodub AN, Koh BD, Xing G, Armstrong AJ, Carducci MA. Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 09 15; 28(18):3979-3989.  View on PubMed
  16. Westbrook TC, Guan X, Rodansky E, Flores D, Liu CJ, Udager AM, Patel RA, Haffner MC, Hu YM, Sun D, Beer TM, Foye A, Aggarwal R, Quigley DA, Youngren JF, Ryan CJ, Gleave M, Wang Y, Huang J, Coleman I, Morrissey C, Nelson PS, Evans CP, Lara P, Reiter RE, Witte O, Rettig M, Wong CK, Weinstein AS, Uzunangelov V, Stuart JM, Thomas GV, Feng FY, Small EJ, Yates JA, Xia Z, Alumkal JJ. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. Nat Commun. 2022 09 15; 13(1):5345.  View on PubMed
  17. Chen HY, Bok RA, Cooperberg MR, Nguyen HG, Shinohara K, Westphalen AC, Wang ZJ, Ohliger MA, Gebrezgiabhier D, Carvajal L, Gordon JW, Larson PEZ, Aggarwal R, Kurhanewicz J, Vigneron DB. Improving multiparametric MR-transrectal ultrasound guided fusion prostate biopsies with hyperpolarized <sup>13</sup> C pyruvate metabolic imaging: A technical development study. Magn Reson Med. 2022 12; 88(6):2609-2620.  View on PubMed
  18. Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A, Korhonen OV, Munzur AD, Beja K, Schönlau E, Bernales CQ, Ritch E, Bacon JVW, Lack NA, Nykter M, Aggarwal R, Small EJ, Gleave ME, SU2C/PCF West Coast Prostate Cancer Dream Team, Quigley DA, Feng FY, Chi KN, Wyatt AW. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature. 2022 08; 608(7921):199-208.  View on PubMed
  19. Zhao N, Chopra S, Trepka K, Wang YH, Sakhamuri S, Hooshdaran N, Kim H, Zhou J, Lim SA, Leung KK, Egusa EA, Zhu J, Zhang L, Foye A, Sriram R, Chan E, Seo Y, Feng FY, Small EJ, Chou J, Wells JA, Aggarwal R, Evans MJ. CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clin Cancer Res. 2022 07 15; 28(14):3066-3075.  View on PubMed
  20. Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Cancer Res Commun. 2022 Jul; 2(7):570-576.  View on PubMed

Go to UCSF Profiles, powered by CTSI